In today’s briefing:
- AbbVie Inc (ABBV US): Great Value Stock to Buy in Choppy Market
AbbVie Inc (ABBV US): Great Value Stock to Buy in Choppy Market
- Abbvie Inc (ABBV US) shares remained rangebound in 2021, mainly due to Humira patent expiration overhang. Humira is the flagship drug of the company, accounting for 37% of total revenue.
- Increasing label expansion of its two other drugs, Skyrizi and Rinvoq are now increasingly opening up new growth avenues for AbbVie. Together these drugs contributed 8% to total revenue.
- Attractive valuation and healthy dividend yield make AbbVie a top value investment idea amid this turbulent time.
Before it’s here, it’s on Smartkarma
